Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans

Robin Pettit, George Pettit, Kevin C. Hazen

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


The biosynthetic peptide dolastatin 10 is currently in phase I and II cancer clinical trials. We evaluated the antifungal spectrum of dolastatin 10 and four structural modifications. In broth macrodilution assays, the peptides were fungicidal for American Type Culture Collection strains and clinical isolates (including fluconazole-resistant strains) of Cryptococcus neoformans but no other yeasts or filamentous fungi examined. Specificity for C. neoformans was also demonstrated in the solid-phase disk diffusion assay, and fungicidal activity was confirmed in time-kill experiments. For a methyl ester modification, the MICs at which 50 and 90% of 19 clinical isolates were inhibited (MIC50 and MIC90, respectively) were 0.195 and 0.39 μg/ml, respectively. The MFC50 (50% minimum fungicidal concentration) for this peptide was 0.39 μg/ml, and the MFC90 was 0.78 μg/ml. MICs and MFCs were identical or lower in the presence of human serum but increased with lowered pH. These peptides should be pursued as potential chemotherapeutics for C. neoformans, a leading cause of infection and mortality in immunocompromised patients.

Original languageEnglish (US)
Pages (from-to)2961-2965
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Issue number11
StatePublished - Nov 1998

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans'. Together they form a unique fingerprint.

Cite this